ЭССЕНЦИАЛЬНАЯ ГИПЕРТЕНЗИЯ С НЕФРОПАТИЕЙ. НАСКОЛЬКО ЭТО АКТУАЛЬНО В НАШИ ДНИ?
https://doi.org/10.24884/1561-6274-2008-12-2-16-22
Аннотация
В обзоре приведены данные крупных проспективных и ретроспективных исследований о распространенности эссенциальной гипертензии с развитием нефропатии в мире, основанные на результатах длительных наблюдений за большими выборками. Представлены основные механизмы участия почек в развитии эссенциальной гипертензии, а также гистологические изменения, возникающие в почечной ткани при данной патологии.
Об авторе
А. М. Есаян
Санкт-Петербургский государственный медицинский университет им. акад. И. П. Павлова
Россия
Россия
кафедра нефрологии и диализа
197022, Россия, Санкт-Петербург, ул. Л. Толстого, 17, тел./факс: 8(812)-234-91-91
Список литературы
1. Смирнов АВ, Добронравов ВА, Каюков ИГ. Кардиоренальный континуум: патогенетические основы превентивной нефрологии. Нефрология 2005; 9 (3): 7–14
2. Есаян АМ. Антигипертензивная терапия и прогрессирование почечной недостаточности. Consilium Medicum 2001; (10): 38–43
3. Caetano ERSP, Zatz R, Saldanha LB, Praxedes JN. Hypertensive nephrosclerosis as a relevant cause of chronic renal failure. Hypertension 2001; 38: 171–176
4. Coresh J, Astor BC, Greene T et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: third national health and nutrition examination survey. Am J Kidney Dis 2003; 41: 1–12
5. Chobanian A, Bakris GL, Black HR et al. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. JAMA 2003; 289: 2560–2572
6. United States Renal Data System. USRDS 2000 Annual Data Report 2000
7. Perry HM Jr, Miller JP, Fornoff JR et al. Early predictors of 15-year end-stage renal disease in hypertensive patients. Hypertension 1995; 25: 587–594
8. MacMahon S, Cutler JA, Stamler J. Antihypertensive drug treatment: potential, expected and observed effects on stroke and on coronary heart disease. Hypertension 1989; 13 [Suppl 1]: 45–50
9. National High Blood Pressure Education Program Working Group. National High Blood Pressure Education Program Working Group Report on hypertension and chronic renal failure. Arch Intern Med 1991; 151: 1280-1287
10. Mazzuchi N, Schwedt E, Fernandez JM et al. Latin American Registry of dialysis and renal transplantation: 1993 annual dialysis data report. Nephrol Daial Transplant 1997; 12: 2521–2527
11. Ministry of Health. Assistance to patients with chronic renal disease. Brasilia, Brazil 1997.
12. D’Amico G. Comparability of different registries of renal replacement therapy. Am J Kidney Dis 1995; 25 (1): 113–118
13. Agodoa LY, Eggers PW. Renal replacement therapy in the United States: data from United States Renal Data System. Am J Kidney Dis 1995; 25: 119–133
14. Бикбов БТ, Томилина НА. О состоянии заместительной терапии больных с хронической почечной недостаточностью в Российской Федерации в 1998–2003 гг. Нефрология и диализ 2005; (3): 204–265
15. Volhard F, Fahr T. Die Bright’sche Nierenkrankheit. Berlin, Julius Springer Verlag 1914
16. Perera GA. Hypertensive vascular disease; description and natural history. J Chronic Dis 1955; 1: 33–42
17. Beevers DG, Lip GY. Does non-malignant essential hypertension cause renal damage? A clinician’s view. J Hum Hypertens 1996; 10: 695–699
18. Klag MJ, Whelton PK, Randall BL et al. Blood pressure and end-stage renal disease in men. N Engl J Med 1996; 334: 13–18
19. Iseki K. The Okinawa Screening Program. J Am Soc Nephrol 2003; 14 (Suppl): S127-S130
20. Fox CS, Larson MG, Leip EP et al. Predictors of new-onset kidney disease in a community-based population. JAMA 2004; 291: 844–850
21. Reynolds K, Gu D, Muntner P et al. A Population-Based, Prospective Study of Blood Pressure and Risk for End-Stage Renal Disease in China. J Am Soc Nephrol 2007; 18: 1928–1935
22. Hsu CY, McCulloch CE, Darbinian J et al. Elevated Blood Pressure and Risk of End-stage Renal Disease in Subjects Without Baseline Kidney Disease. Arch Intern Med 2005; 165 (4): 923–928
23. Ludwig T. Uber den Zusammenhang von Herz- und Nierenkrankheiten. Berlin, Germany: August Hirschwald 1856
24. Mahomed FA. On chronic Bright’s disease and its essential symptoms. Lancet 1879; 76 (1): 46–57
25. Ruilope LM, Lahera V, Rodicio JL and Carlos Romero J. Are renal hemodynamics a key factor in the development and maintenance of arterial hypertension in humans? Hypertension 1994; 23 (1): 3–9
26. Cowley AW Jr, Roman RJ. The role of the kidney in hypertension. JAMA 1996; 275 (20): 1581–1589
27. Bidani AK, Griffin KA. Pathophysiology of hypertensive renal damage. Hypertension 2004; 44: 595–602
28. Borst JGG, Borst-de Geuss A. Hypertension explained by Starling’s theory of circulatory homeostasis. Lancet 1963; 30 (1): 677–682
29. Guyton AC, Coleman TG, Cowley AW Jr et al. Arterial pressure regulation: overriding dominance of the kidneys in long-term regulation and in hypertension. Am J Med 1972; 52 (4): 584–594
30. Guyton AC. Renal function curve: A key to understanding the pathogenesis of hypertension. Hypertens 1987; 10: 1–6
31. Dahl LK, Heine M. Primary role of renal homografts in setting chronic blood pressure levels in rats. Circ Res 1975; 36 (5): 692-696
32. Fox U, Bianchi G. The primary role of the kidney in causing blood pressure difference between the Milan hypertensive strain (MHS) and normotensive rats. Clin Exp Pharmacol Physiol 1976; 3 [Suppl. 3]: 71–74
33. Kawabe K, Watanabe TX, Shiono K, Sokabe H. Influence on blood pressure of renal isografts between spontaneously hypertensive and normotensive rats, utilizing F1 hybrids. Jpn Heart J 1978; 19 (7): 886–894
34. Curtis JJ, Luke RG, Dustan HP et al. Remission of essential hypertension after renal transplantation. N Engl J Med 1983; 309: 1009–1014
35. Keller G, Zimmer G, Mall G et al. Nephron number in patients with primary hypertension. N Engl J Med 2003; 348: 101–108
36. Brenner BM, Garsia DL, Anderson S. Glomeruli and blood pressure. Less of one, more of the other? Am J Hypertens 1988; 1: 335–347
37. Lifton RP. Molecular genetics of human blood pressure variation. Science 1996; 272: 676–680
38. Weinberger MH. Salt sensitivity of blood pressure in humans. Hypertension 1996; 27 (part 2): 481–939
39. Midgley JP, Matthew AG, Greenwood CM, Logan AG. Effect of reduced dietary sodium on blood pressure: a meta-analysis of randomised controlled trials. JAMA 1996; 275: 1590–1597
40. Каюков ИГ, Есаян АМ, Кучер АГ, Ермаков ЮА. Роль функционально-гемодинамических механизмов в прогрессировании хронического гломерулонефрита. Нефрология 1998; 2 (1): 7–14
41. Guidi E, Bianchi G, Rivolta E et al. Hypertension in man with a kidney transplant: Role of familial versus other factors. Nephron 1985; 41: 14–21
42. Schmid M, Meyer S, Wegner R, Ritz E. Increased genetic risk of hypertension in glomerulonephritis? J Hypertens 1990; 8: 573–577
43. Fagerudd JA, Tarnow L, Jacobsen P et al. Predisposition to essential hypertension and development of diabetic nephropathy in IDDM patients. Diabetes 1998; 47: 439–444
44. Strojek K, Grzeszczak W, Morawin E et al. Nephropathy of type II diabetes: Evidence for hereditary factors? Kidney Int 1997; 51: 1602–1607
45. Sealey JE. Plasma renin activity and plasma prorenin assays. Clin Chem 1991; 37: 1811–1819
46. Mattson DL, Maeda CY, Bachman TD, Cowley AW Jr. Inducible Nitric Oxide Synthase and Blood Pressure. Hypertension 1998; 31: 15–24
47. Johnson RJ, Herrera-Acosta J, Schreiner GF et al. Subtle acquired renal injury as a mechanism of salt-sensitive hypertension. N Engl J Med 2002; 346 (12): 913–923
48. Goldblatt H. The renal origin of hypertension. Physiol Rev 1947; 27: 120–132
49. Moritz AR, Oldt MR. Arteriolar sclerosis in hypertensive and nonhypertensive individuals. Am J Pathol 1937; 13: 679–728
50. Серов ВВ, Яргин СВ. Морфо- и патогенез нефросклероза: клинико-морфолгический анализ. Тер архив 1986; 58 (8): 4–9
51. Мационис АЭ, Батюшин ММ, Повилайтите ПЕ, Литвинов АС. Морфологический анализ патологических изменений в почках в зависимости от длительности артериальной гипертензии. Нефрология 2007; 11 (3): 55–59
52. Sommers SC, Relman AC, Smithwick RH. Histologic studies of kidney biopsy specimens from patients with hypertension. Am J Pathol 1958; 34: 685–715
53. Moritz AR, Oldt MR. Arteriolar sclerosis in hypertensive and nonhypertensive individuals. Am J Pathol 1937; 13: 679–728
54. Kincaid-Smith P. Clinical diagnosis of hypertensive nephrosclerosis. Nephrol Dial Transplant 1999; 14: 2255–2256
55. Caetano EP, Zatz R, Praxedes JN. The clinical diagnosis of hypertensive nephrosclerosis – how reliable is it? Nephrol Dial Transplant 1999; 14: 288–290
56. Kincaid-Smith P. The prevention of renal failure. In: Villarreal H, ed. Proceedings of the Fifth International Congress of Nephrology Mexico. S. Karger, Basel 1972: 100–118
57. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic (The antihypertensive and lipid lowering treatment to prevent heart attack trial – ALLHAT). JAMA 2002; 288: 2981–2997
58. Luke RH. Hypertensive nephrosclerosis: pathogenesis and prevalence. Nephrol Dial Transplant 1999; 14: 2271–2278
59. Мухин НА, Балкаpов ИМ, Соничев ДГ, Лебедева МВ. Фоpмиpование аpтеpиальной гипеpтонии пpи уpатном тубулоинтеpстициальном поpажении почек. Тер архив 1999; 71 (6): 23–29
60. Kanellis J, Nakagawa T, Herrera-Acosta J et al. A single pathway for the development of essential hypertension. Cardiol Rev 2003; 11: 180–196
61. Kimmelsteil P, Wilson C. Benign and malignant hypertension and nephrosclerosis. A clinical and pathological study. Am J Pathol 1936; 12: 45–81
62. Sommers SC, Relman AC, Smithwick RH. Histologic studies of kidney biopsy specimens from patients with hypertension. Am J Pathol 1958; 34: 685–715
63. Sommers SC, Melamed J. Renal pathology of essential hypertension. Am J Hypertens 1990; 3: 583–587
64. Jones DB. Arterial and glomerular lesions associated with severe hypertension.Lab Invest 1974; 31: 303–313
65. Gуmez DM. Evaluation of renal resistances, with special reference to changes in essential hypertension. J Clin Invest 1951; 30: 1143–1155
66. Goldring W, Chasis H, Ranges HA, Smith HW. Effective renal blood flow and functional excretory mass in essential hypertension. J Clin Invest 1938; 17: 505–509
67. de Leeuw PW, Birkenhдger AM. The renal circulation in essential hypertension. J Hypertens 1983; 1: 321–331
68. Bohle A, Wehrmann M, Greschniok A, Junghaus R. Renal morphology in essential hypertension: Analysis of 1177 unselected cases. Kidney Int 1998; 54 [Suppl 67]: S205–S206
69. Bohle A, Ratschek M. The compensated and the decompensated form of benign nephrosclerosis. Path Res Pract 1982; 174: 357–367
70. Rasmussen H, Boe J. The prognosis of essential hypertension, with remarks respecting the indications for operative treatment. Acta Med Scand 1945; 120: 12–31
71. Talbott JH, Castleman B, Smithwick RH et al. Renal biopsy studies correlated with renal clearance observations in hypertensive patients treated by radical sympathectomy. J Clin Invest 1943; 22: 387–394
Рецензия
Для цитирования:
Есаян А.М. ЭССЕНЦИАЛЬНАЯ ГИПЕРТЕНЗИЯ С НЕФРОПАТИЕЙ. НАСКОЛЬКО ЭТО АКТУАЛЬНО В НАШИ ДНИ? Нефрология. 2008;12(2):16-22. https://doi.org/10.24884/1561-6274-2008-12-2-16-22
For citation:
Essaian A.M. ESSENTIAL HYPERTENSION WITH NEPHROPATHY, HOW ACTUAL IS IT NOWADAYS? Nephrology (Saint-Petersburg). 2008;12(2):16-22. (In Russ.) https://doi.org/10.24884/1561-6274-2008-12-2-16-22
Просмотров:
378
Послать статью по эл. почте 